Literature DB >> 16552801

Apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action.

Wen-He Zhao1, Shi-Fu Wang, Wei Ding, Jian-Ming Sheng, Zhi-Min Ma, Li-Song Teng, Min Wang, Fu-Sheng Wu, Bing Luo.   

Abstract

AIM: To study the apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action.
METHODS: Sixty gastric cancer patients were divided randomly into three groups (20 each group) before operation: group one:5'-DFUR oral administration at the dose of 800-1200 mg/d for 3 - 5 d, group two: 500 mg 5-FU + 200 mg/d CF by venous drip for 3 - 5 d,group three (control group). One or two days after chemotherapy, the patients were operated. Fas/FasL,PD-ECGF and PCNA were examined by immunohistochemistry and apoptotic tumor cells were detected by in situ TUNEL method. Fifty-four patients received gastrectomy, including 12 palliative resections and 42 radical resections. Six patients were excluded. Finally 18 cases in 5'-DFUR group, 16 cases in CF+5-FU group, and 20 cases in control group were analyzed.
RESULTS: There was no significant difference in patient mean age, gender, white blood cell count, haematoglobin (HB),thromboplastin, perioperative complication incidence, radical or palliation resection, invasion depth (T), lymphonode involvement (N),metastasis (M) and TNM staging among the three groups. However,the PCNA index (PI) in 5'-DFUR group (40.51+/-12.62) and 5-FU+CF group (41.12+/-15.26) was significantly lower than that in control group (58.33+/-15.69) (F=9.083, P=0.000). The apoptotic index (AI) in 5'-DFUR group (14.39+/-9.49) and 5-FU+CF group (14.11+/-9.68)was significantly higher than that in control group (6.88+/-7.37) (F=4.409, P=0.017).The expression rates of Fas and FasL in group one and group three were 66.7% (12/18) and 50% (9/18), 43.8% (7/16) and 81.3% (13/16), 45.0% (9/20) and 85% (17/20), respectively. The expression rate of FasL in 5'-DFUR group was significantly lower than that in the other two groups (chi2=6.708, P=0.035). Meanwhile, the expression rate of PD-ECGF was significantly lower in 5'-DFUR group (4/18,28.6%) than in CF+5-FU group(9/16,56.3%)and control group (13/20,65.0%) (chi2=7.542, P=0.023). The frequency of Fas expression was significantly correlated with palliative or radical resection (chi2=7.651, P=0.006), invasion depth (chi2=8.927, P=0.003), lymphatic spread (chi2=4.488, P=0.034) and UICC stages (chi2=8.063, P=0.045) respectively. By the end of March 2005,45 patients were followed up. The 0.5-, 1-, 2-, 3-year survival rates were 96%,73%,60%,48%, respectively, which were related with T, N, M and Fas expression, but not with PD-ECGF and FasL expression.
CONCLUSION: Preoperative oral 5'-DFUR administration may induce apoptosis of gastric carcinoma cells and decrease tumor cell proliferation index,but cannot improve the prognosis of patients with gastric cancer.Down-regulation of FasL and PD-ECGF expression mediated by 5'-DFUR may be one of its anti-cancer mechanisms.Fas expression correlates with the progression of gastric carcinoma and may be an effective prognostic factor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16552801      PMCID: PMC4124310          DOI: 10.3748/wjg.v12.i9.1356

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  47 in total

1.  [Detection and significance of lymph node micrometastases in patients with histologically node-negative gastric carcinoma].

Authors:  A Zhao; J Li; W Sun
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2000-05

2.  Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis.

Authors:  H Nagashima; M Mori; N Sadanaga; K Mashino; Y Yoshikawa; K Sugimachi
Journal:  Int J Oncol       Date:  2001-06       Impact factor: 5.650

3.  Clinicopathological and prognostic significance of thymidine phosphorylase expression in gastric carcinoma.

Authors:  K Ogawa; S Konno; Y Takebayashi; K Miura; T Katsube; T Kajiwara; M Aiba; T Aikou; S Akiyama
Journal:  Anticancer Res       Date:  1999 Sep-Oct       Impact factor: 2.480

4.  Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma.

Authors:  S Koyama; N Koike; S Adachi
Journal:  J Cancer Res Clin Oncol       Date:  2001-01       Impact factor: 4.553

5.  Clinicopathological and prognostic significance of thymidine phosphorylase and proliferating cell nuclear antigen in gastric carcinoma.

Authors:  S Konno; Y Takebayashi; M Aiba; S Akiyama; K Ogawa
Journal:  Cancer Lett       Date:  2001-05-10       Impact factor: 8.679

6.  A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs.

Authors:  S T Eichhorst; M Müller; M Li-Weber; H Schulze-Bergkamen; P Angel; P H Krammer
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

7.  Thymidine phosphorylase expression results in a decrease in apoptosis and increase in intratumoral microvessel density in human gastric carcinomas.

Authors:  M Osaki; T Sakatani; E Okamoto; E Goto; H Adachi; H Ito
Journal:  Virchows Arch       Date:  2000-07       Impact factor: 4.064

8.  [Long-term outcome of preoperative chemotherapy with 5'-deoxy-5-fluorouridine (5'-DFUR) for gastric cancer].

Authors:  T Kobayashi; T Kimura
Journal:  Gan To Kagaku Ryoho       Date:  2000-09

9.  Genetic polymorphisms of Fas (CD95) and FasL (CD178) in human longevity: studies on centenarians.

Authors:  M Pinti; L Troiano; M Nasi; L Moretti; E Monterastelli; A Mazzacani; C Mussi; P Ventura; F Olivieri; C Franceschi; G Salvioli; A Cossarizza
Journal:  Cell Death Differ       Date:  2002-04       Impact factor: 15.828

10.  Expression of Bcl-2 inhibited Fas-mediated apoptosis in human hepatocellular carcinoma BEL-7404 cells.

Authors:  Y C Chang; Y H Xu
Journal:  Cell Res       Date:  2000-09       Impact factor: 25.617

View more
  5 in total

Review 1.  Postoperative morbidity and mortality in patients receiving neoadjuvant chemotherapy for locally advanced gastric cancers: A systematic review and meta-analysis.

Authors:  Huiyu Luo; Liucheng Wu; Mingwei Huang; Qinwen Jin; Yuzhou Qin; Jiansi Chen
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

2.  COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis.

Authors:  Tom van den Ende; Frank A Abe Nijenhuis; Héctor G van den Boorn; Emil Ter Veer; Maarten C C M Hulshof; Suzanne S Gisbertz; Martijn G H van Oijen; Hanneke W M van Laarhoven
Journal:  Front Oncol       Date:  2019-07-25       Impact factor: 6.244

3.  Postoperative morbidity and mortality after neoadjuvant chemotherapy versus upfront surgery for locally advanced gastric cancer: a propensity score matching analysis.

Authors:  Liucheng Wu; Lianying Ge; Yuzhou Qin; Mingwei Huang; Jiansi Chen; Yang Yang; Jianhong Zhong
Journal:  Cancer Manag Res       Date:  2019-07-03       Impact factor: 3.989

Review 4.  Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials.

Authors:  A-Man Xu; Lei Huang; Wei Liu; Shuang Gao; Wen-Xiu Han; Zhi-Jian Wei
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

Review 5.  Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?

Authors:  Rossella Reddavid; Silvia Sofia; Paolo Chiaro; Fabio Colli; Renza Trapani; Laura Esposito; Mario Solej; Maurizio Degiuli
Journal:  World J Gastroenterol       Date:  2018-01-14       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.